UCB to sell Kremers Urban to private equity for US$1.53bn

Published: 10-Nov-2014
Finance Pharmaceutical

Belgian company will focus on its core business in neurology and immunology

UCB is selling its US speciality generics business Kremers Urban to private equity firms Advent International and Avista Capital Partners for US$1.53bn.

Belgium-headquartered UCB plans to use the proceeds to reduce its debt and increase its investments to accelerate growth and strengthen its medicines pipeline.

The deal is expected to close during the first quarter of 2015.

'This is another step for UCB to enhance focus on our core business in neurology and immunology,' said Roch Doliveux, CEO of UCB.

Detlef Thielgen, Chief Financial Officer of UCB, added that Kremers Urban had been 'an important enabler to build UCB's core business'.

'It's now the right time from a value perspective to focus on our core business and to offer Kremers Urban further growth opportunities with two strong organisations that are well equipped to help Kremers Urban continue to grow.'

  • Companies:
  • UCB
See more

You may also like

Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Read more
Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  4. Lonza aims to tackle bias concerns during blinded clinical trials Lonza has introduced an over-encapsulation product aimed at tackling concerns around bias during blinded clinical trials
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes
Packaging

Pharmapack Europe 2019 reveals winners

Award winners have been selected for innovation in delivery, dosage and packaging of pharmaceutical products
Pharmaceutical

Increasing competition in the psoriasis market

UCB, a global biopharmaceutical company, has potential to compete in the psoriasis market with Cimzia FDA approval, says GlobalData
Drug Delivery

UCB receives EMA approval for pre-filled pen using Bespak Technology

First disposable autoinjector for a biologic with Bespak technology to be approved by CHMP
Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Manufacturing

CPI-led UK biotech consortium secures £6.2m of government investment

Project aims to reduce the time it takes to bring biologics to market
Subscribe now